Key Points
- Insider sale: Scott Bizily sold 1,635 shares of 4D Molecular Therapeutics at an average price of $13.65, reducing his holdings by 15.95% to 8,617 shares. He has also made three other sales since August.
- Business and stock performance: FDMT opened at $15.88, near its 52-week high of $16.93, while the company reported a quarterly loss of $1.04 per share and revenue of $3.78 million. Analysts expect a full-year loss of $4.07 per share.
- Analyst outlook remains positive: The stock has a consensus “Moderate Buy” rating and an average price target of $28.56, despite one sell rating. Institutional investors own approximately 99.27% of the company.
4D Molecular Therapeutics, Inc. (NASDAQ:FDMT - Get Free Report) insider Scott Bizily sold 1,635 shares of the firm's stock in a transaction on Wednesday, September 16th. The shares were sold at an average price of $13.65, for a total transaction of $22,317.75. Following the sale, the insider owned 8,617 shares in the company, valued at approximately $117,622.05. This trade represents a 15.95% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link.
Scott Bizily also recently made the following trade(s):
- On Tuesday, September 1st, Scott Bizily sold 584 shares of 4D Molecular Therapeutics stock. The shares were sold at an average price of $14.00, for a total value of $8,176.00.
- On Thursday, August 13th, Scott Bizily sold 1,635 shares of 4D Molecular Therapeutics stock. The stock was sold at an average price of $12.00, for a total value of $19,620.00.
- On Monday, August 17th, Scott Bizily sold 1,635 shares of 4D Molecular Therapeutics stock. The shares were sold at an average price of $12.20, for a total value of $19,947.00.
4D Molecular Therapeutics Stock Performance
Shares of NASDAQ FDMT opened at $15.88 on Wednesday. The stock's 50-day moving average is $12.95 and its 200 day moving average is $10.95. The stock has a market cap of $877.21 million, a price-to-earnings ratio of -6.04 and a beta of 2.74. 4D Molecular Therapeutics, Inc. has a 1-year low of $6.96 and a 1-year high of $16.93. The company has a current ratio of 8.03, a quick ratio of 8.03 and a debt-to-equity ratio of 0.05.
4D Molecular Therapeutics (NASDAQ:FDMT - Get Free Report) last issued its quarterly earnings results on Thursday, August 13th. The company reported ($1.04) EPS for the quarter, missing analysts' consensus estimates of ($1.02) by ($0.02). The business had revenue of $3.78 million for the quarter, compared to the consensus estimate of $3.62 million. 4D Molecular Therapeutics had a negative net margin of 194.74% and a negative return on equity of 41.33%. On average, sell-side analysts anticipate that 4D Molecular Therapeutics, Inc. will post -4.07 EPS for the current fiscal year.
Institutional Investors Weigh In On 4D Molecular Therapeutics
Several institutional investors and hedge funds have recently bought and sold shares of the business. Persistent Asset Partners Ltd purchased a new position in shares of 4D Molecular Therapeutics during the second quarter valued at approximately $1,936,000. Deutsche Bank AG purchased a new stake in 4D Molecular Therapeutics in the second quarter worth $9,456,000. Dimensional Fund Advisors LP lifted its position in shares of 4D Molecular Therapeutics by 77.3% in the 1st quarter. Dimensional Fund Advisors LP now owns 522,823 shares of the company's stock worth $4,863,000 after purchasing an additional 227,982 shares during the period. Exome Asset Management LLC bought a new position in shares of 4D Molecular Therapeutics in the 1st quarter worth approximately $1,216,000. Finally, Bank of America Corp DE lifted its stake in shares of 4D Molecular Therapeutics by 17.0% in the 1st quarter. Bank of America Corp DE now owns 974,173 shares of the company's stock valued at $9,070,000 after purchasing an additional 141,582 shares during the period. Hedge funds and other institutional investors own 99.27% of the company's stock.
Wall Street Analysts Forecast Growth
FDMT has been the subject of several recent research reports. The Goldman Sachs Group reissued a "buy" rating and issued a $32.00 price target on shares of 4D Molecular Therapeutics in a research note on Thursday, August 13th. B. Riley Financial reaffirmed a "buy" rating on shares of 4D Molecular Therapeutics in a research note on Monday, August 17th. HC Wainwright reiterated a "buy" rating and issued a $36.00 price objective on shares of 4D Molecular Therapeutics in a report on Monday, July 20th. Weiss Ratings reissued a "sell (d-)" rating on shares of 4D Molecular Therapeutics in a research note on Friday, July 17th. Finally, Chardan Capital upgraded 4D Molecular Therapeutics to a "strong-buy" rating in a research report on Tuesday, July 28th. One equities research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and a consensus price target of $28.56.
Get Our Latest Research Report on 4D Molecular Therapeutics
4D Molecular Therapeutics Company Profile
(
Get Free Report)
4D Molecular Therapeutics, Inc is a clinical-stage biotechnology company developing genetic medicines for serious diseases with significant unmet medical needs. The company uses its Therapeutic Vector Evolution platform to engineer and select adeno-associated virus (AAV) vectors designed to deliver genetic payloads to specific tissues and support the development of potentially durable, one-time treatments.
Its research and development programs have focused primarily on ophthalmic and pulmonary diseases.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
